Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares of 45.65M shares in Q2 FY2026

Q2 FY2026 weighted avg shares was 45.65M shares.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
45.65M+18.5% QoQ
Last fiscal yearDec 2025
43.03M+0.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
43.03M USD
Year-over-year change
+0.0%
1-year CAGR
+0.0%

Weighted Avg Shares vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 weighted avg shares of 43.03M shares is the 7th highest of the 11 companies compared; the peer median is 58.34M shares.
  • Its year-over-year change of +0.0% is the 8th highest of 10, against a peer median of +5.5%.
ATTO Competitors Peer median
Weighted Avg Shares for ATTO and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.7%+384.0%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
ORKAOruka Therapeutics, Inc.LTM Sep 202661.01M +68.6%+46.8%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
EVMNEvommune, Inc.LTM Mar 202631.7M ——
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
Peer median (excluding ATTO) 58.34M+5.5%+38.4%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.